We are live on ! Find out more
ACM

Asymmetry Capital Management Portfolio holdings

AUM $188M
1-Year Est. Return 44.72%
This Fund
S&P 500
This Quarter Est. Return
+14.66%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$86.2M
AUM Growth
+$1.9M
Cap. Flow
-$5.96M
Cap. Flow %
-6.91%
Top 10 Hldgs %
59.3%
Holding
39
New
11
Increased
6
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$4.06M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$2.93M
3
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$2.81M
4
NVTA
Invitae Corporation
NVTA
+$2.79M
5
HMSY
HMS Holdings Corp.
HMSY
+$2.64M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$4.2M
2
MDT icon
Medtronic
MDT
+$4.05M
3
GILD icon
Gilead Sciences
GILD
+$4.05M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.58M
5
PTCT icon
PTC Therapeutics
PTCT
+$3.38M

Sector Composition

Rank Sector Weight
1 Healthcare 90.93%
2 Industrials 3.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
26
Heron Therapeutics
HRTX
$94.5M
$1.02M 1.18%
+62,962
New +$988K
REGN icon
27
Regeneron Pharmaceuticals
REGN
$79.5B
$998K 1.16%
+2,233
New +$1.06M
SNNA
28
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$926K 1.07%
+41,622
New +$914K
AERI
29
DELISTED
Aerie Pharmaceuticals
AERI
$874K 1.01%
17,975
-7,489
-29% -$409K
SGYP
30
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$786K 0.91%
271,102
-101,592
-27% -$347K
RGNX icon
31
Regenxbio
RGNX
$722M
$443K 0.51%
13,448
-458
-3% -$10.3K
CBMX
32
DELISTED
CombiMatrix Corporation
CBMX
$245K 0.28%
+32,641
New +$221K
GILD icon
33
Gilead Sciences
GILD
$162B
– –
-57,157
Closed -$4.05M
GSK icon
34
GSK
GSK
$104B
– –
-34,598
Closed -$1.86M
IRWD icon
35
Ironwood Pharmaceuticals
IRWD
$701M
– –
-61,405
Closed -$971K
ICPT
36
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-29,570
Closed -$3.58M
ATRS
37
DELISTED
Antares Pharma, Inc.
ATRS
– –
-199,655
Closed -$643K
ALXN
38
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-12,210
Closed -$1.49M
OXFD
39
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-16,212
Closed -$273K
1
2

Similar funds

FAC
Forrestal Agricultural Corporation Princeton, New Jersey $183M AUM
SWM
Strategic Wealth Management Kirkland, Washington $202M AUM 9.35% 1-Year Est. Return
MC
MRJ Capital New York $173M AUM 31.99% 1-Year Est. Return
KM
Kylin Management New York $173M AUM 39.51% 1-Year Est. Return
TI
Truehand Inc Strafford, New Hampshire $171M AUM 25.9% 1-Year Est. Return
GC
Grace Capital Quincy, Massachusetts $168M AUM 21.6% 1-Year Est. Return
REMS
Real Estate Management Services $167M AUM 37.69% 1-Year Est. Return
NM
Nokota Management New York $165M AUM

Asymmetry Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Asymmetry Capital Management held 39 positions worth $86.2M, up 2.3% from $84.3M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Asymmetry Capital Management withdrew a net $5.96M in Q3 2017, closing 7 positions and reducing 15 holdings. Its most notable exit was Gilead Sciences, an estimated $4.05M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 98% a quarter earlier, followed by Industrials.

Against the trend, Asymmetry Capital Management opened a new position in Insmed worth $6.66M.

  • Asymmetry Capital Management's largest Q3 2017 buy was Insmed: 213,376 shares worth $6.66M.
  • Asymmetry Capital Management added most to Natera in Q3 2017, an estimated $1.92M increase.
  • Asymmetry Capital Management's biggest Q3 2017 reduction was NEVRO CORP., cutting an estimated $4.2M.
  • Asymmetry Capital Management fully exited Gilead Sciences in Q3 2017, selling an estimated $4.05M.
  • Asymmetry Capital Management's ten largest holdings make up 59% of its $86.2M portfolio in Q3 2017.
  • Asymmetry Capital Management opened 11 new positions and closed 7 in Q3 2017.
  • Asymmetry Capital Management's portfolio value rose 2.3% quarter-over-quarter to $86.2M.

Based on Asymmetry Capital Management's 13F filing for Q3 2017, filed 3 Nov 2017.